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Zn binding motifThe Vif protein of primate lentiviruses interacts with APOBEC3 proteins, which results in shunting of the
APOBEC3-Vif complex to the proteosome for degradation. Using the simian-human immunodeﬁciency virus
(SHIV)/macaque model, we compared the replication and pathogenicity of SHIVs that express a Vif protein
in which the entire SLQYLA (SHIVVif5A) or HCCH (SHIVVifHCCH(−)) domains were substituted with alanine
residues. Each virus was inoculated into three macaques and various viral and immunological parameters
followed for 6 months. All macaques maintained stable circulating CD4+ T cells, developed low viral loads,
maintained the engineered mutations, yielded no histological lesions, and developed immunoprecipitating
antibodies early post-inoculation. Sequence analysis of nef and vpu from three lymphoid tissues revealed a
high percentage of G-to-A-substitutions. Our results show that while the presence of HCCH and SLQYLA
domains are critical in vivo, there may exist APOBEC3 negative reservoirs that allow for low levels of viral
replication and persistence but not disease.olecular Genetics and Immunol-
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Human immunodeﬁciency virus type 1 (HIV-1) and other
lentiviruses encode for a Vif (virion infectivity factor) protein, which
has been shown to be essential for HIV-1 replication in primary CD4+
T cells and macrophages (Fan and Peden, 1992; Gabuzda et al., 1992;
Blanc et al., 1993; Sakai et al., 1993; von Schwedler et al., 1993;
Borman et al., 1995). The Vif protein interacts with apolipoprotein B
mRNA editing enzyme catalytic peptide-like 3G (APOBEC3G; hA3G)
promoting its accelerated degradation by the proteosome (Sheehy
et al., 2003). APOBEC3G is a cytidine deaminase that, if packaged into
HIV-1Δvif virions, induces cytidine deamination of newly synthesized
minus-strand viral DNA from cytosines to uracils, leading to G to A
transitions in plus strand synthesis (Jarmuz et al., 2002; Harris et al.,
2003; Mariani et al., 2003; Mangeat et al., 2003; Sheehy et al., 2003;
Yu et al., 2004a). The RNA editing activity of the APOBEC3 family ofproteins involves an active site characterized by a conserved zinc-
binding motif, (Cys/His)-Xaa-Glu-Xaa23–28-Pro-Cys-Xaa2–4-Cys, con-
taining a glutamate involved in proton shuttling during deamination
(Jarmuz et al., 2002). In addition to A3G, humans have six other
APOBEC3 genes; hA3A, hA3B, hA3C, hA3DE, hA3F, and hA3H (Jarmuz
et al., 2002). Of those APOBEC3 genes, hA3B, hA3DE, hA3G, and hA3F,
have been shown to inhibit the replication of HIV-1Δvif (Dang et al.,
2006, 2008; Doehle et al., 2005; Wiegand et al., 2004; Yang et al.,
2007; Yu et al., 2004b; Zheng et al., 2004). SIVmac239Δvif has been
shown to be restricted by hA3G, hA3F, hA3B, hA3C, hA3DE (Dang et
al., 2006, 2008; Mariani et al., 2003; Yu et al., 2004b; Zennou and
Bieniasz, 2006). The HIV-1 Vif has limited activity against rhesus and
African green monkey A3 proteins while Vif from SIVmac239 and
SIVagm have broader speciﬁcities. While less is presently known about
the rhesus A3 proteins, it is known that HIV-1Δvif can be inhibited by
rhA3G, rhA3F, rhA3B, and to a lesser extent rhA3H and rhA3DE
(Virgen and Hatziioannou, 2007). SIVmac239Δvif has been shown to be
restricted by rhA3G, rhA3F, rhA3C, rhA3B and rhA3DE, and to a lesser
extent rhA3H (Virgen and Hatziioannou, 2007; Zennou and Bieniasz,
2006).
188 K. Schmitt et al. / Virology 404 (2010) 187–203Sequence analysis of Vif proteins from different lentiviruses
reveals that there are two highly conserved domains in the carboxyl
terminus, the SLQ(Y/F)LA and Zn++ binding (HCCH) motifs.
Previous cell culture studies with hA3 proteins showed that
introduction of amino acid substitutions in the viral BC box (SLQ
(Y/F)LA) resulted in decreased binding of Vif to Elongin C while
substitutions in the HCCH domain prevent interactions with Cullin 5
of the Cul5/Elongin B/C/Rbx E3 ligase complex (Luo et al., 2005;
Mehle et al., 2004a,b, 2006; Stopak et al., 2003; Yu et al., 2003,
2004c). These studies showed increased A3G incorporation into
virions and G-to-A hypermutation (Mangeat et al., 2003; Shindo et
al., 2003; Zhang et al., 2003). Our laboratory has been using the
chimeric simian-human immunodeﬁciency (SHIV)/macaque model
to study the role of Vpu and its various domains in CD4+ T cell loss,
virus release and pathogenesis (Stephens et al., 2002; Singh et al.,
2003; Hout et al., 2005; 2006; Hill et al., 2008). In this study, we
constructed simian-human immunodeﬁciency viruses (SHIVs) in
which ﬁve amino acids in the SLQYLA motif (SHIVVif5A) and four
amino acids of the HCCH (SHIVVifHCCH(−)) domain were changed to
alanine residues. Our results indicate that rhA3F is stable in the
presence of wild type and mutant Vif viruses and that rhA3G is more
effective at cytidine deamination than rhA3F. Our results show that
both the HCCH and SLQYLA domains were critical to Vif function in
vivo but that production of viral RNA only persisted in macaques
inoculated with the SHIVVifHCCH(−).
Results
Replication of SHIVVif5A and SHIVVifHCCH(−) in APOBEC3 positive and
negative cell lines
The sequence of the Vif mutants that were analyzed in this study
are shown in Fig. 1.We performed assays to examine the replication of
parental SHIVKU-2MC4, SHIVVif5A, SHIVVifHCCH(−), SHIVVifAAQYLA and
SHIVVifSTOP in hA3G/F positive (C8166) and negative (SupT1) cell
lines as well as rhesus PBMC (rhA3G/F+). We included SHIVVifAAQYLA
in these growth curves for comparison as we previously reported on
the replication of this mutant in tissue culture and in macaques
(Schmitt et al., 2009). Cells were inoculated with equivalent amounts
(25 ng of p27) each of the virus and the levels of p27 Gag released into
the culture medium were quantiﬁed using a commercial antigen
capture assay. All four mutant viruses (SHIVVif5A, SHIVVifHCCH(−),
SHIVVifAAQYLA and SHIVVifSTOP) replicated in SupT1 cells to similar
levels as parental SHIVKU-2MC4 by day 15 post-inoculation, although
the kinetics of replication were slower (Fig. 2A). Inoculation of
equivalent amounts (25 ng p27) of SHIVVif5A, SHIVVifHCCH(−),
SHIVVifAAQYLA, and SHIVVifSTOP into hA3G/F+C8166 cell cultures
resulted in less than 0.01% of the p27 released compared to parental
SHIVKU-2MC4 (Fig. 2B). As shown in Fig. 2C, in rhesus PBMC SHIVKU-2MC4
replicated to high levels (7.932 ng/ml) while SHIVVifHCCH(−)
(0.119 ng/ml) and SHIVVif5A (0.197 ng/ml), and SHIVVifAAQYLA
(0.11 ng/ml) replicated to low but detectable levels. Replication
was undetectable for SHIVVifSTOP in rhesus PBMC.Fig. 1. Sequence of the wild type SIVmac239 Vif protein and the two mutants analyzed in th
underlined. The amino acid substitutions in the SHIVVif5A and SHIVVifHCCH(-) are also underlBoth SHIVVif5A and SHIVVifHCCH(−) incorporate rhA3G and rhA3F into
virus particles
The above results suggested that hA3G and hA3F or rhA3G and
rhA3Fmight be incorporated into maturing virus particles resulting in
restriction of replication. As we are most interested in rhA3G and
rhA3F, we transfected 293 cells with plasmids expressing an HA-
tagged rhA3G or a V5-tagged rhA3F and the complete genomes of
either SHIVVif5A, SHIVVifHCCH(−), SHIVVifSTOP, or parental SHIVKU-2MC4.
At 48 h post-transfection, the culture medium was collected, clariﬁed,
and the virus partially puriﬁed and concentrated by ultracentrifuga-
tion. Equal amounts of p27 (as determined by Western blot) were
loaded and analyzed for the presence or absence of rhA3G or rhA3F.
The results shown in Fig. 3A indicate that rhA3G was incorporated
into SHIVVif5A, SHIVVifHCCH(−), and SHIVVifSTOP virus particles but was
excluded from SHIVKU-2MC4 particles. However, we found that the
rhA3F protein was incorporated into all four viruses (Fig. 3B). These
results indicate that rhA3G was selectively incorporated only into the
Vif mutants while rhA3F was incorporated into all viruses. The
inability of SIVmac239 Vif to degrade and prevent the incorporation of
rhA3F has been previously reported (Virgen and Hatziioannou, 2007).
Rhesus A3F is stable in the presence of SIVmac239 Vif
Since we observed that rhA3F was incorporated into virus
particles, we determined the stability of rhA3F and rhA3G in the
presence of the viral genome. 293 cells were co-transfected with
vectors expressing rhA3G or rhA3F and the genomes of SHIVKU-2MC4,
SHIVVif5A, SHIVVifHCCH(−), or SHIVVifSTOP. Our results indicate that in the
presence of the SHIVKU-2MC4 genome, rhA3Gwas not stable whereas it
was detected in the presence of the SHIVVif5A, SHIVVifHCCH(−) or
SHIVVifSTOP (Fig. 4). We also found that rhA3F appeared to be stable in
the presence of both SHIVKU-2MC4 and also SHIVVif5A, SHIVVifHCCH(−), or
SHIVVifSTOP genomes. However, it should be noted thatwe consistently
found higher levels of rhA3F in the presence of the SHIVVifSTOP genome,
indicating fundamental differences between the targeting site-
directed Vif mutants and the absence of the Vif protein. The results
obtained with rhA3F correlate well with the above experiment
showing that rhA3F was incorporated into virus particles.
Rhesus A3G but not rhA3F causes signiﬁcant G-to-A mutations in the nef
gene of the SHIV genome
The results above indicated that signiﬁcant levels of rhA3F were
incorporated into virions and rhA3F was stable in cells expressing the
wild type genome. We compared the level of G-to-A mutations of the
SHIV genomes in the presence of either rhA3G or rhA3F. The results
are shown in Fig. 5 and Table 1. Using viral genomes to express the Vif
protein, we observed minimal G-to-A changes in SHIVKU-2MC4 nef in
the presence of either rhA3G or rhA3F. In the presence of rhA3G, we
found that SHIVVif5A, SHIVVifHCCH(−) or SHIVVifSTOP nef had an increase
in the number of G-to-A changes (from 2 to 24–29) or approximately
0.5% of the bases sequenced (Table 1). However, in the presence ofis study. The amino acids comprising the Zn+2 and BC box domains are italicized and
ined.
Fig. 2. Replication of SHIVVif5A, SHIVVifHCCH(−), SHIVVifAAQYLA, SHIVVifSTOP, and
SHIVKU-2MC4 in SupT1 cells (hA3G/F negative), C8166 cells (hA3G/F positive), and
rhesusmacaque PBMC. Cells were inoculatedwith equal amounts of each virus (25 ng of
p27) and the levels of p27 in the culture supernatants were assessed at various times
post-inoculation. Panel A. Replication of viruses in SupT1 cells. Panel B. Replication of
viruses in C8166 cells. Panel C. Replication of viruses in rhesus PBMC. (▲) SHIVVif5A, (□)
SHIVVifAAQYLA(●) SHIVVifHCCH(−), (♦) SHIVVifSTOP and (■)SHIVKU-2MC4.
Fig. 3. The incorporation of rhA3Gand rhA3F into virus particles. 293 cellswere transfected
with a plasmid that expressed the genome of either SHIVKU-2MC4, SHIVVif5A, SHIVVifHCCH(−),
or SHIVVifSTOP and a vector expressing HA-rhA3G or V5-rhA3F. At 48 h, the culturemedium
was collected, clariﬁed by low speed centrifugation, and concentrated by ultracentrifuga-
tion through a 20/60 (w/v) step-gradient. Equivalent levels of p27 (determined by
Western blot) from each sample were resuspended in sample reducing buffer, boiled, and
the proteins were separated by SDS-PAGE. The presence of either rhA3G or rhA3F was
detected by Western blot using an antibody directed against the HA-tag or V5 tag,
respectively. Panel A. Results of rhA3G incorporation. Lane 1. rhA3G proteins detected in a
lysate fromcells transfectedwithvector expressing rhA3Galone. Lanes2–5. rhA3Gproteins
detected in virus from cells transfected with vector expressing rhA3G and SHIVKU-2MC4
(Lane2), SHIVVif5A (Lane3), andSHIVVifHCCH(−) (Lane4); andSHIVVifSTOP (Lane5). InLane6,
rhA3Gproteins in thepelleted supernatant fromcells transfectedwith emptyvectors. Panel
B. Blot in Panel A stripped and reprobed with an antibody against p27 protein. Panel C.
Results of incorporation of rhA3F. Lane 1. rhA3F proteins detected in a lysate from cells
transfectedwith vector expressing rhA3F alone. Lanes 2–5. rhA3Fproteins detected in virus
from cells transfected with vector expressing rhA3F and SHIVKU-2MC4 (Lane 2), SHIVVif5A
(Lane 3), and SHIVVifHCCH(−) (Lane 4); and SHIVVifSTOP (Lane 5). In Lane 6, rhA3F proteins in
the pelleted supernatant from cells transfectedwith empty vectors. Panel D. Blot in Panel C
stripped and reprobed with an antibody against p27 protein.
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had a similar level of G-to-A changes compared to SHIVKU-2MC4
(Table 1). The results with rhA3F suggest that incorporation of rhA3F
does not result in signiﬁcant G-to-A substitutions in nef.Fig. 4. Stability of the rhA3G and rhA3F in the presence of wild type and Vif mutant viral
genomes. Full-length mutated SHIVs were co-transfected into 293 cells with a vector
expressing either HA-rhA3G or V5-rhA3F. At 24 h post-transfection, cells were lysed
and proteins were precipitated using methanol. Proteins were separated on a 10% SDS-
PAGE gel and probed using an antibody directed against either the HA or V5-tag. All
samples were normalized to the amount of β-actin protein. Panel A. Stability of rhA3G
in the presence of SHIVVifSTOP (lane 3), SHIVKU-2MC4 (lane 4), SHIVVif5A (Lane 5), or
SHIVVifHCCH(−) (Lane 6). Lanes 1 and 2 were used as a positive (rhA3G only; Lane 1) or
negative (pcDNA3.1(+) only; Lane 2) control. Panel B. Stability of rhA3F in the
presence of SHIVKU-2MC4 (Lane 3), SHIVVif5A (Lane 4), SHIVVifHCCH(−) (Lane 5), or
SHIVVifSTOP (Lane 6). Lanes 1 and 2were used as a negative (pcDNA3.1(+) only; Lane 1)
or positive (rhA3F only; Lane 2) control.
Fig. 5. Rhesus A3G but not rhA3F induces G-to-A mutations in single colony sequences obtained from nef. Full-length genomes of the wild type and Vif mutant viruses were co-
transfected with vectors expressing either rhA3G or rhA3F into 293 cells. At 48 h post-transfection, the culture mediumwas collected, clariﬁed by low speed centrifugation and used
to infect TZM-bl cells. A 325 base pair fragment of nefwas ampliﬁed from DNA at 24 h post-infection and assessed for G-to-A substitutions. Panel A. G-to-A mutations obtained from
bulk (top line) and 15 independent clone sequences are shown. Each mutation is denoted by a vertical line that is color coded with respect to the dinucleotide context: non-G-to-A
(black), GA to GA (red), GG to AA (yellow), GT to AT (cyan), or GC to AC (gray). Panels B and C. Graphs depicting the cumulative number of mutations from the 15 clones per virus in
the presence of rhA3G and rhA3F, respectively. Post-transfection Panel C. Each bar is shaded according to the proportion of G-to-A-substitutions that occurred in the context of non-
G-to-A (black). GA to AA (red), GG to AG (yellow), GT to AT (Cyan), GC to AC (gray).
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virus replication
Weexamined thegrowthof SHIVVif5A, SHIVVifSTOP, andSHIVVifHCCH(−)
in the presence rhA3G or rhA3F restricted the production of infectious
virus. 293 cells were transfected with the genomes of SHIVVif5A,
SHIVVifHCCH(−), SHIVVifSTOP, or SHIVKU-2MC4 and a plasmid expressing
either an HA-tagged rhA3G, V5-tagged rhA3F or the empty vector. At
48 h, the virus containing supernatant was collected, clariﬁed byTable 1
Results of the hypermutation assay of nef ampliﬁed by rhA3G and rhA3F in the presence of
APOBEC3 protein Virus aTotal number of
bases sequenced
Total
G-to-
rhA3G SHIVKU-2MC4 4875 2 (0
rhA3G SHIVVif5A 4875 24 (0
rhA3G SHIVVifHCCH(−) 4875 26 (0
rhA3G SHIVVifSTOP 4875 29 (0
rhA3F SHIVKU-2MC4 4875 2 (0
rhA3F SHIVVif5A 4875 1 (0
rhA3F SHIVVifHCCH(−) 4875 2 (0
rhA3F SHIVVifSTOP 4875 3 (0
a A 325 base fragment corresponding to the 5' end of nef was ampliﬁed, cloned and 15 incentrifugation, and the p27 levels quantiﬁed. Equivalent levels of p27
from each virus stock were used to titrate infectious virus by a series of
10-fold dilutions onto TZM.bl cells. At 48 h, the cells were stained for β-
galactosidase activity (β-galactosidase is under the control of the LTR
andexpressionof Tat fromthe incomingvirus)and thenumberof TCID50
determined. If rhA3G or rhA3F was packaged into the virions, the virus
should be hypermutated resulting in the expression of a non-functional
Tat. As shown in Fig. 6A, SHIVKU-2MC4 replicated to approximately the
same levels in the presence or absence (empty vector) of rhA3G whilewild type and mutant Vif proteins.
# of G-to-A mutations/percent
A mutations of bases sequenced
Number and context of cytidine
deamination
5'-GA 5'-GG 5'-GC
.04) 1 1 0
.49) 23 0 1
.53) 21 1 4
.59) 27 2 0
.04) 1 1 0
.02) 1 0 0
.04) 1 1 0
.06) 2 1 0
dividual clones were selected for sequence analysis.
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fold less than the unmodiﬁed virus (SHIVKU-2MC4). With rhA3F, our
results indicate that SHIVKU-2MC4, SHIVVifHCCH(−) and SHIVVif5A had an
approximate 10-fold decrease in titers and SHIVVifSTOP had greater than a
1000-fold decrease in titer (Fig. 6B). The results with rhA3F also
emphasize the differences in site-directed mutations in SHIVVifHCCH(−),
SHIVVif5A and the severely truncated Vif in SHIVVifSTOP.
Assessment of SHIVVifHCCH(−) replication in macaques
We inoculated three macaques with 104 TCID50 of SHIVVifHCCH(−).
Prior to inoculation, macaques AS34, AS51, and AV18 had
circulating CD4+ cell levels of 1,509, 1,109, and 400 cells per μl,
respectively. These three macaques maintained levels of circulating
CD4+ T cells at pre-inoculation levels or higher throughout the
course of the 6-month infection (Fig. 7A). All three macaques were
euthanized at 26–28 weeks post-inoculation in excellent condition.
At necropsy, AS34, AS51, and AV18 had circulating CD4+ T cell
levels of 2,124, 1,338, and 1,298 cells/μl, respectively. This contrasts
with macaques inoculated with parental SHIVKU-2MC4, which
developed a severe loss of circulating CD4+ T cells within 3–4 weeks
post-inoculation (Fig. 7C). Analysis of the plasma viral loads revealed aFig. 6. Incorporation of rhA3G results in less infectious virus. 293 cells were co-
transfected with the SHIVKU-2MC4, SHIVVif5A, and SHIVVifHCCH(−) and SHIVVifSTOP
genomes and plasmids expressing either rhA3G or rhA3F. Controls included co-
transfection of each viral genome with empty plasmids (pcDNA3.1(+)). At 48 h, the
culture medium was harvested, assessed for p27, and the amount of infectious virus
titrated on the TZM.bl cells as described inMaterials andmethods. Shown are infectious
titers in the absence or presence of either rhA3G (Panel A) or rhA3F (Panel B).mean viral load of 4.15×103 copies per ml at 1 week post-inoculation
(Fig. 8A), which is approximately 10,000-fold less than the macaques
inoculated with parental SHIVKU-2MC4 (Fig. 8C). Following the ﬁrst
week of infection, the plasma viral loads in macaques AS34, AS51, and
AV18 were at or just above the limits of detection. At necropsy, viral
loads in all three macaques were undetectable. These results indicate
that SHIVVifHCCH(−) transiently replicated in these macaques prior to
control of the infection.
Assessment of SHIVVif5A replication in macaques
We also assessed the ability of SHIVVif5A to replicate in three
macaques (CX54, ER65, and I92). Prior to inoculation, macaques
CX54, ER65, and I92 had circulating CD4+ T cell levels of 777, 844,
and 1,451 cells per μl, respectively (Fig. 7B). These macaques,
similar to those inoculated with SHIVVifHCCH(−), maintained circu-
lating CD4+ T cell levels near the pre-inoculation levels throughout
the course of the 6-month infection. All three macaques were
euthanized at 26 weeks post-inoculation in excellent condition. At
necropsy, CX54, ER65, and I92 had circulating CD4+ T cell levels of
513, 853, and 1192 cells per μl, respectively (Fig. 7B). This also
contrasts with macaques inoculated with parental SHIVKU-2MC4
(Fig. 7C). Analysis of the plasma viral loads of the macaques
inoculated with SHIVVif5A revealed a mean viral load of 1.3×103
copies per ml at 1 week post-inoculation (Fig. 8B). Following the
ﬁrst week of infection, the plasma viral loads in macaques CX54,
ER65, and I92 fell to undetectable levels.
Mutations in vif ampliﬁed from isolated DNA of PBMC during the course
of infection
We assessed the stability of the engineered mutations in the vif
gene from DNA isolated PBMC throughout the course of infection.
The vif sequence was ampliﬁed, directly sequenced and compared to
the input vif sequence of SHIVVif5A or SHIVVifHCCH(−). We observed
that the engineered mutations were stable throughout the course of
the 6-month infection for macaques inoculated with SHIVVifHCCH(−).
We performed bulk sequencing of the vif ampliﬁed at 1, 2, 3, 4, 6,
and 16 weeks. As shown in Fig. 9, the number of G-to-A mutations in
the ampliﬁed vif gene increased with time in two (AS51, AV18) of
the three macaques while the third macaque (AS34) appeared to
have the largest number of G-to-A mutations at 3 weeks post-
inoculation. As we had reported earlier, the majority of the G-to-A
mutations were in the context of the 5'-TC (minus strand) rather
than 5'-CC (Schmitt et al., 2009). We were able to amplify part of the
vif sequence at 1 week from PBMC DNA isolated from macaques
inoculated with SHIVVif5A (CX54,ER65, I92). The sequence analysis
also revealed that these vif mutations were stable at 1 week post-
inoculation (data not shown). However, from 3 weeks until
necropsy, we were unable to amplify the vif gene, which correlates
with the undetectable plasma viral loads in these macaques after
week 1 post-inoculation.
Macaques inoculated with SHIVVif5A and SHIVVifHCCH(−) developed
anti-viral antibody responses early after inoculation
We analyzed the plasma from infected macaques at 12 weeks and
at necropsy (26–28 weeks) for the presence of immunoprecipitating
antibody responses. At 12 weeks post-inoculation, all three macaques
inoculated with SHIVVif5A had developed antibody responses to p27
but only macaque ER65 developed antibody responses to the Env
glycoprotein (Fig. 10A). For macaques inoculated with SHIVVifHCCH(−),
all three macaques developed antibodies to p27 and the Env
glycoprotein (Fig. 10A). At necropsy, we could not detect the presence
of immunoprecipitating antibodies from macaques inoculated with
either SHIVVif5A or SHIVVifHCCH(−) (Fig. 10B). A macaque inoculated
Fig. 8. Plasma viral loads in macaques inoculated with SHIVVifHCCH(−), SHIVVif5A, and
SHIVKU-2MC4 as determined by real time quantitative PCR. Panel A. Plasma viral loads in
three macaques (AS34, ●; AS51, ■; and AV18, ▲) following inoculation with
SHIVVifHCCH(−). Panel B. Plasma viral loads in three macaques (CX54, ●; ER65, ■; and
I92, ▲) following inoculation with SHIVVif5A. Panel C. The plasma viral loads in three
macaques (44O, ●; 44 N, ■;35 N , ▲) following inoculation with SHIVKU-2MC4.
Fig. 7. Circulating CD4+ T cell levels in macaques inoculated with SHIVVifHCCH(−),
SHIVVif5A, and SHIVKU-2MC4. Panel A. The levels of circulating CD4+ T cells in three
macaques (AS34, ●; AS51, ■; and AV18, ▲) following inoculation with SHIVVifHCCH(−).
Panel B. The levels of circulating CD4+ T cells in threemacaques (CX54,●; ER65,■; and
I92, ▲) following inoculation with SHIVVif5A. Panel C. The levels of circulating CD4+ T
cells in threemacaques (44O,●; 44 N,■; 35 N,▲) following inoculationwith SHIVKU-2MC4.
192 K. Schmitt et al. / Virology 404 (2010) 187–203with parental SHIVKU-2MC4 (44O) did not develop antibodies to the
virus at either time point, which is common for macaques that
develop severe CD4+ T cell loss during the acute phase (b4 weeks)
following inoculation with a pathogenic X4 SHIV (data not shown).
Fig. 9. Analysis of vif sequences ampliﬁed fromDNA isolated from PBMC at various times
post-inoculation. Panel A. Quantitative representation of mutations induced in bulk
sequences obtained from a 450 base pair fragment of SHIVVifHCCH(−) Vif. Each vertical bar
represents the total number of G-to-A substitutions. Each bar is shaded according to the
proportion of G-to-A-substitutions the occurred in the context of GA (red), GG (yellow),
GT (cyan), or non-G-to-A (black). Panel B. A 450 base pair fragment of the SIV Vif was
ampliﬁed using DNA isolated from macaque PBMC inoculated with SHIVVifHCCH(−).
Mutations from bulk sequence analysis from eachmacaque are shown. Each mutation is
denoted by a vertical line that is color coded with respect to the dinucleotide context:
non-G-to-A mutations (black), GA-to-AA (red), GG-to-AG (yellow), or GT-to-AT (cyan).
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macaques inoculated with SHIVVif5A and SHIVVifHCCH(−)
Tissues from infectedmacaqueswere examined for the presence of
lesions consistent with this pathogenic X4 SHIV (Joag et al., 1998).
Macaques inoculated with either SHIVVif5A or SHIVVifHCCH(−) did not
exhibit histological lesions in any of the 13 visceral organs examined
or in the CNS (data not shown). As the plasma viral loads were
signiﬁcantly less than macaques inoculated with SHIVKU-2MC4, we
assessed the tissue distribution of these two viruses in macaques. RNA
was isolated from 13 visceral organs from macaques inoculated with
SHIVVif5A and SHIVVifHCCH(−), DNase I treated, and copy numbers
determined by real time quantitative RT-PCR. The number of copies is
expressed per 106 copies of GADPH. The results obtained from
macaques inoculated with SHIVVifHCCH(−) are shown in Fig. 11A–C.We
found that macaque AS34 had eight tissues (kidney, lung, pancreas,
axillary lymph node, inguinal lymph node, spleen, thymus and tonsil)
greater than 1000 copies per 106 copies of GAPDH (Fig. 11A). Macaque
AS51 was found to have two tissues (lung and small intestine) with
greater than 1000 copies per 106 copies of GAPDH, andmacaque AV18had six tissues (lung, pancreas, axillary lymph node, inguinal lymph
node, mesenteric lymph node and spleen) with greater than 1000
copies per 106 copies of GAPDH (Fig. 11B–C). Interestingly, the lung
had the highest viral copy number in each macaque. In contrast, we
were unable to quantify viral RNA from the tissues of macaques that
were inoculated with SHIVVif5A (data not shown). Macaques inocu-
lated with parental SHIVKU-2MC4, 44O and 44 N, had high copy
numbers of virus in various tissues (Fig. 11D). Taken together, these
results indicate that both SHIVVifHCCH(−) and SHIVVif5A infections were
signiﬁcantly less widespread compared to macaques inoculated with
parental SHIVKU-2MC4.
G-to-A mutations in nef and vpu ampliﬁed from DNA of primary and
secondary lymphoid organs
A well documented feature of HIV-1Δvif infection is the incorpo-
ration of select APOBEC3 proteins into viral particles leading to
cytosine deamination during minus strand DNA synthesis (Yu et al.,
2003). This results in hypermutation (guanosine to adenosine
transitions) of the viral genome and inhibition of virus replication.
We examined the number of G-to-A mutations in the nef and vpu
genes ampliﬁed from DNA isolated from one primary lymphoid organ
(thymus) and two secondary lymphoid organs (ileum of the small
intestine and spleen) from the three macaques inoculated with
SHIVVifHCCH(−) and one macaque inoculated with SHIVKU-2MC4. We
ﬁrst PCR ampliﬁed nef and vpu sequences from tissue DNA, subcloned
and sequenced 15 individual clones. The results showed that there
were multiple G-to-A mutations in the nef and vpu regions ampliﬁed
from three tissues. The number of G-to-Amutations ranged from 54 to
88 or 1.2% to 1.9% of the total base pairs sequenced (Fig. 12;Table 2).
While the percentage of mutations observed in the vpu was lower
(perhaps reﬂecting the gradient of mutations from nef to vpu), the
overall number of G-to-A mutations in the context of 5'-TC (minus
strand) to 5'-CC was approximately 2:1 (75 versus 31 mutations)
(Fig. 13; Table 3). We plotted the G-to-A mutations obtained from 15
single colony sequences of nef and vpu ampliﬁed from DNA isolated
from the ileum of macaques inoculated with SHIVVifHCCH(−) (Figs. 12
and 13). These results showed that many of the G-to-A mutations
found in the direct bulk sequencing products were also found in the
individually cloned genes (Figs. 12 and 13). Similar to what we
reported previously, the majority of the changes were in the context
of 5'-TC (minus strand) (Tables 2 and 3). Macaque 44O, (inoculated
with SHIVKU2-MC4) had very few G-to-A substitutions in vpu and nef
ampliﬁed from the same three lymphoid organs, which is similar to
other macaques inoculated with this parental virus (unpublished
observations). Macaque AV18 yielded the highest number of G-to-A
substitutions (88) in the ileum of the small intestine. Taken together
these ﬁndings suggest that one or more rhA3 proteins have target
sequence preference for 5'-TC is themajor cytidine deaminase at work
in vivo.
Discussion
There are only a limited number of studies that have analyzed the
role of the Vif protein in the SIV or SHIV/macaque models of HIV-1
disease. In the ﬁrst study, the role of various accessory proteins
expressed from SIVmac239 was evaluated in terms of the potential to
cause disease (Desrosiers et al., 1998). These investigators found that
an SIV with deletion of vif had only transient viral loads, could only be
detected in PBMC for a short period of time and the macaques did not
produce antibodies against SIV proteins. In a second study, investi-
gators showed that a vif-deleted virus would generate antibody and
cellular immune responses if the virus was administered 2–3 times
but was not protective against challenge (Sparger et al., 2008). In both
studies, the lymphoid and non-lymphoid tissues were not examined
for the presence of viral RNA from these vif-deleted viruses. Finally, we
Fig. 10.Macaques inoculatedwithSHIVVif5A andSHIVVifHCCH(−) developedantibody responses against eachvirus at 12weekspost- inoculation. C8166 cellswere inoculatedwithSHIVKU-
2MC4 for 5 days, starved formethionine/cysteine and then radiolabeled overnight with 35 S-methionine/cysteine. The culturemediumwas harvested and used in immunoprecipitation
reactionswithplasma fromAS34, AS51, AV18, CX54, ER65, and I92 as described in theMaterials andMethods section. The immunoprecipitateswerewashedwith 1×RIPA buffer, boiled
in 2× sample reducing buffer, proteins were separated on 12% SDS-PAGE gels, and visualized using autoradiographic techniques. Panel A. SHIV proteins immunoprecipitated with
plasma obtained at 12 weeks post-inoculation. The molecular weight standards are shown on the left. Panel B. SHIV proteins immunoprecipitated with plasma obtained at necropsy.
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into the SLQYLA domain of Vif (to AAQYLA) resulted in a virus
(SHIVVifAAQYLA) that did not replicate well in hA3G/F positive cells.
However, following inoculation into macaques, the plasma viral loads
were lowered from approximately 107 copies per ml for wild type
virus to approximately 105 copies per ml for the SHIVVifAAQYLA during
the acute phase of infection (Schmitt et al., 2009). In these macaques,
the levels of circulating CD4+ T cells were maintained near pre-
inoculation levels and the macaques did not develop histological
lesions consistent with a pathogenic X4 SHIV. Sequence analysis of the
vif gene ampliﬁed from the PBMC revealed that the engineered
AAQYLA motif had mutated to TAQYLA in two of three macaques.
Since serine and threonine are hydroxylated amino acids that differ by
a methyl group, it was possible that these Vif proteins may have been
“partially” functional in vivo to permit limited spread within
macaques. Examination of the tissues from these macaques revealed
that viral RNA was present in select tissues, and the viral sequences
contained low levels of G-to-A substitutions. We also showed that the
inoculation of plasma from two of these macaques into a naive
macaque did not result in detectable viral loads up to 5 months post-
inoculation (Schmitt et al., 2009). Thus, despite the low level of viral
replication in cell culture systems, SHIVVifAAQYLA was still capable of
signiﬁcant in vivo replication, thus validating the need to examine
targeted Vif mutants in macaques.
In the present study, we have extended our in vivo studies using
SHIVmutants that express either a Vif protein with the ﬁrst ﬁve amino
acids of the SLQYLA domain substituted with alanines (SHIVVif5A) or a
Vif with the HCCH domain substituted with alanines (SHIVVifHCCH(−)).
Interestingly, our restriction assays showed that incorporation of
rhA3G but not rhA3F resulted in the greatest reduction of replication,
which is somewhat different from the results previously reported
(Zennou and Bieniasz, 2006). Our results indicate that unlike the
parental virus, both mutant viruses incorporated rhA3G while both
the parental and mutant viruses incorporated rhA3F into virions. Our
analysis of rhA3F and rhA3G stability in the presence of viral genome
indicated that rhA3F is stable while rhA3G is degraded. The
incorporation of rhA3F into wild type virions is in agreement with a
previous study (Zennou and Bieniasz, 2006; Virgen and Hatziioannou,
2007). These paradoxical ﬁndings suggest that rhA3F can be
incorporated in the presence of SIVmac Vif and that the virus canseemly replicate without the accumulation of lethal mutations. In the
former study, these investigators found that rhA3F was resistant to
the SIVmac Vif protein. They suggested that rhA3F may not exert a
strong negative presence on SIVmac in vivo and that the SIVmac Vif may
actually permit some degree of mutagenesis by rhA3F. This was
supported by analysis of HIV-1 gag, pol, and env for potential editing
sites (GG or GA) that would yield a termination codon if mutated.
Their analysis revealed that the percentage of GA editing sites leading
to termination codons was lower than GG sites in the gag, pol, and env.
Analysis of the SIV gag, pol, vif, vpr, vpx, and nef (the SIV genes of our
SHIV) also revealed this trend (unpublished observations) yet the
mutations observed in the SIVmac nef were predominantly in the
context of GA and not GG. Whether this was due to lethal GG-to-AG
mutations that were subsequently cleared (or not detectable) or
whether this was due to rhA3F or other rhA3 proteins is unknown at
this time. However, it should be noted that there were differences
between our study and the previous study. First, in the previous study
the investigators used a HIV-1Δvif genome and we used an SIV-based
viral genome with targeted mutations in the vif. We showed that
replication of SHIVVifSTOP was much lower compared to SHIVVif5A and
SHIVVifHCCH(−) in the presence of rhA3F. Thus, the results of
SHIVVifSTOP in our study and HIV-1Δvif in their study are comparable.
Our study also shows that our viruses with targeted mutations
(SHIVVif5A and SHIVVifHCCH(−)) were restricted less efﬁciently in the
presence of rhA3F compared to SHIVVifSTOP, suggesting that the
presence of an intact, “crippled” Vif protein can impose some
restriction compared to having a Δvif virus. This may relate to the
ability of the VifHCCH(−) and the Vif5A proteins to still bind to rhA3F.
Previous studies have deﬁned regions of the HIV-1 Vif that are
required for binding various hA3 proteins. Many of these regions are
in the amino terminal region of the protein. Previous studies
demonstrated that HIV-1 Vif residues 40YRHHY44 and 12QVDRMR17
are important for the interaction with hA3G and hA3F/C, respectively
(Russell and Pathak, 2007; Mehle et al., 2007). In a more recent study,
a conserved YXXL domain at residues 69–72 of the HIV-1 Vif was
found to be important for the interaction of Vif with hA3G, hA3F and
hA3C (Pery et al., 2009). While the 12QVDRMR17 and 40YRHHY44 are
not conserved in the SIVmac239 Vif, there is a lysine at position 27 of
the SIVmac Vif that is required for interaction with rhA3G (Chen et al.,
2009; Dang et al., 2009). The YWGL domain of the HIV-1 Vif is also
Fig. 11. Comparison of viral copy numbers in the visceral tissues of macaques inoculated with SHIVVifHCCH(−) and SHIVKU-2MC4. RNA was isolated from different visceral organs of
macaques inoculated with SHIVVifHCCH(−) or SHIVKU-2MC4, DNase I treated to remove residual DNA and used in real time quantitative RT-PCR using oligonucleotide primers speciﬁc
for gag as described inMaterials andmethods. The levels of viral RNA are shown per 106 copies of GADPH RNA. Panels A–C. The results of the real time quantitative RT-PCR using RNA
isolated from tissues of macaques AS34 (Panel A), AS51 (Panel B) and AV18 (Panel C), which were inoculated with SHIVVifHCCH(−). Panel D. The results of the real time quantitative
RT-PCR using RNA isolated from tissues of macaque 44O, which was inoculated with SHIVKU-2MC4. The dotted line represents the limits of detection of this assay.
195K. Schmitt et al. / Virology 404 (2010) 187–203conserved in the SIV Vif (as YWHL). Thus, it is possible that the Vif
proteins with targeted amino acid substitutions may still bind and
incorporate rhA3F into virus particles but may be inefﬁcient in
deamination because of its association with Vif. A second difference in
the two studies is the hypermutation assay used to analyze the
percentage of G-to-A changes in the genome. While the previous
study showed that rhA3F caused G-to-A hypermutation at levels
higher than rhA3G, we found that rhA3F produced little hypermuta-
tion in the viral genome. In the previous study, these investigators
used a VSV pseudotyped HIV-1 vector with the vif deleted as well as
other genes and analyzed hrGFP sequences. In our system, we used
complete SIV viral genomes expressing the Vif mutants.
One goal of these studies was to determine if SHIVVif5A was
effectively controlled by macaques during the primary phase ofinfection or if viral variants would emerge that would permit limited
replication in macaque tissues. Our results indicate that following
inoculation of SHIVVif5A into macaques, there was a further reduction
of plasma viral loads compared to SHIVVifAAQYLA (Schmitt et al., 2009).
The mean peak plasma virus load (week 1) was 1.3×103 viral copies
per ml or approximately 4000-fold lower than parental SHIVKU-2MC4.
However, following this initial burst of replication, viral RNA from
macaques inoculated with SHIVVif5A was near or below the limits of
detection for this assay (∼180 copies). It should be noted that the
virus was not completely eliminated because viral RNA was
occasionally detected in the plasma throughout the 6-month infection
using nested RT-PCR (data not shown). At necropsy, the number of
copies of viral RNA could not be quantiﬁed from various organs of
these macaques (detection limit 180 copies) but could be detected by
Fig. 12. Quantitative assessment of mutations in the nef gene. Panels A–D. A 300 base pair fragment of nefwas ampliﬁed using DNA isolated from the small intestine (ileum), spleen
and thymus of macaques inoculated with SHIVVifHCCH(−). Mutations obtained using sequence analysis of ﬁfteen independent clones from each macaque is shown. Each vertical bar
represents an individual clone, whose height represents the total number of substitutions. Each bar is shaded according to the proportion of G-to-A-substitutions the occurred in the
dinucleotide context: non-G-to-A (black), GA (red), GG (yellow), GT (cyan), or GC (gray). Panels E–G. Hypermutation plot illustrating the G-to-A and non-G-to-A substitutions in the
clones from the ileum ampliﬁed DNA. Eachmutation is denoted by a vertical line that is color codedwith respect to the dinucleotide context: non G to A (black), GG to AG (yellow), GA
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to AA (red), GT to AT (cyan), and GC to AC (gray).
Fig. 12 (continued).
Table 2
Results of sequence analysis of nef ampliﬁed from the thymus, ileum, and spleen.
Animal
Tissue
aTotal number
of bases
sequenced
Total # of G-to-A
mutations/percent
G-to-A mutations
of bases sequenced
Number and context of
cytidine deamination
5'-GA 5'-GG % 5'-GA to GG
AS34
Thymus 4500 71/1.6 67 4 94.3
Spleen 4500 61/1.4 59 2 96.7
Ileum 4500 83/1.8 82 1 98.7
AS51
Thymus 4500 75/1.7 69 6 92.0
Spleen 4500 62/1.4 62 0 100
Ileum 4500 66/1.5 65 1 98.4
AV18
Thymus 4500 54/1.2 54 0 100
Spleen 4500 58/1.3 54 4 93.1
Ileum 4500 88/2.0 86 2 97.7
a A 300 base fragment corresponding to the 5' end of nef was ampliﬁed, cloned and
15 separate clones sequenced.
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3 weeks post-inoculation and were unable to amplify the nef gene at
necropsy for sequence analysis. While the results presented here may
be predicted based on studies in cell culture systems, these results
demonstrate for the ﬁrst time that a primate lentivirus expressing a
Vif protein with only targeted mutations in a critical domain can be
completely controlled by the host. Taken together, these results
indicate that the SHIVVif5A replicated similarly to a virus that does not
express a functional Vif protein (Desrosiers et al., 1998).
No studies have analyzed the role of the Zn++ binding domain of
Vif in vivo. Previous studies have shown that this domain is critical to
Vif function, interacting with Cul 5 of the Cul 5/ElonginB/C/Rbx E3
ligase (Luo et al., 2005; Xiao et al., 2007). Our results showed that
these macaques had slightly higher initial viral loads at 1 week post-
inoculation than macaques inoculated with SHIVVif5A but that the
virus was effectively controlled by the macaques by 3 weeks post-
inoculation. Similar to our previous study, the majority of the G-to-A
mutations were in the context of 5'-TC (minus strand) and not 5'-CC.
In addition, we observed that the majority of the G-to-A changes
found in the vif gene ampliﬁed from PBMC DNA occurred during the
ﬁrst weeks of infection. This correlated well with the plasma viral
loads which indicated the viral replication primarily occurred during
this time period.
Taken together, our results show that abolishing the SLQYLA
domain of Vif may be more detrimental to the virus in vivo than theHCCH domain. These data bring up the question, “Why were we able
to quantify viral RNA from tissues of macaques inoculated with
SHIVVifHCCH(−) but not SHIVVif5A?” While the answer is unknown,
several possibilities exist. First, the virus may have initially replicated
in cells expressing active rhA3 proteins and incorporated one or more
rhA3 proteins into the viral progeny. In the next round of replication
the genomewasmutated but not to the extent that RNA polymerase II
could not transcribe viral RNA. Second, there may be a tissue/cellular
reservoir for virus replication that do not express the rhA3 proteins
that would restrict the crippled SIVmac239 Vif protein. We previously
showed using immunohistochemistry that rhA3G was not expressed
in all cell types in the brain and kidneys (Hill et al., 2006, 2007).
Finally, during the initial rounds of replication and potential
deamination, G-to-A mutations may have led to compensating
mutations that made the viral Vif partially functional. The latter
scenario is not likely as our sequence analysis did not identify
consensus mutations in either the SHIVVif5A or SHIVVifHCCH(−)-
inoculated macaques.
As previous studies showed that antibody responses were not
generated with a single inoculation of vif-deleted viruses (Desrosiers
et al., 1998; Sparger et al., 2008), we determined if a single inoculation
of either virus would result in an antibody response against viral
proteins. Comparison of the antibody responses from macaques
inoculated with either SHIVVifHCCH(−) or SHIVVif5A shows that at
12 weeks post-inoculation macaques had developed antibody
responses against the virus but these were undetectable at necropsy.
This would argue that the viral RNA detected in tissues at necropsy
may not have been translated into viral proteins. This would also
suggest that infectious virus was cleared by the macaque and that
antigenic stimulation through viral proteins did not occur. However,
this study provides evidence that such viruses containing site-
directed mutations in vif could be used to “prime” the immune
system and suggests that such a virus could be useful in a prime-boost
strategy. It will be of interest to determine if multiple inoculations will
result in stronger immune responses (both humoral and cellular) and
a further reduction of viral loads with increasing inoculations. If
successful, it will be of interest to determine if the immune responses
are protective against challenge. While the use of live attenuated
lentiviruses has led to useful information concerning the role of
accessory genes in replication of the virus in vivo, the use of such
vaccines has several underlying risks (Koff et al., 2006). First, these
vaccines have relied on the deletion/disruption of accessory genes
(nef, vpu, vpx/vpr) that enhance replication but are not absolutely
required for replication in vivo. For this reason these viruses can select
for compensating mutations that ultimately result in the virus
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the risk of recombination of the viral genome to yield a pathogenic
virus (Kim et al., 2005). A vaccine based on a “crippled Vif” that allowsfor limited replication resulting in G-to-A substitutions and inactiva-
tion of the virus should prevent the scenarios discussed above. It
would be of interest to determine if inoculation of macaques with two
Fig. 13. Quantitative assessment of mutations in the vpu gene. Panels A-D. A 184 base
pair fragment of vpu was ampliﬁed using DNA isolated from the ileum, spleen and
thymus of macaques inoculated with SHIVVifHCCH(−) and one macaque inoculated with
SHIVKU-2MC4. Substitutions were determined using sequence analysis of ﬁfteen
independent clones from each macaque are shown. Each mutation is denoted by a
vertical bar that is color coded with respect to the dinucleotide context: non-G to A
(black), GG to AG (yellow), GA to AA (red), GT to AT (cyan), and GC to AC (gray). Panels
E-G. Hypermutation plot illustrating the G-to-A and non-G-to-A substitutions in the
clones obtained from the small intestine (ileum) ampliﬁed DNA. Each mutation is
denoted by a vertical line that is color coded with respect to the dinucleotide context:
non G to A (black), GG to AG (yellow), GA to AA (red), GT to AT (cyan), and GC to AC
Table 3
Results of sequence analysis of vpu ampliﬁed from the thymus, ileum, and spleen.
Animal Tissue aTotal number
of bases
sequenced
Total # of G-to-A
mutations/percent
G-to-A mutations
of bases sequenced
Number and context of
cytidine deamination
5'-GA 5'-GG % 5'-GA to GG
AS34
Thymus 2760 13/0.47 6 6 50.0
Spleen 2760 15/0.54 10 4 71.4
Ileum 2760 15/0.54 8 7 53.3
AS51
Thymus 2760 14/0.51 11 0 100
Spleen 2760 9/0.33 7 2 77.8
Ileum 2760 15/0.54 9 5 64.2
AV18
Thymus 2760 3/0.12 3 0 100
Spleen 2760 30/1.09 16 3 84.2
Ileum 2760 11/0.40 5 4 55.5
a A 184 base fragment corresponding to vpu was ampliﬁed, sub-cloned and 15
independent clones sequenced.
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(gray).viruses, one harboring a mutation in vif and another having a
mutation in another accessory gene such as nef can recombine in
vivo to generate a wild type virus causing CD4+ T cell loss and disease
prior to the virus accumulating G-to-A mutations.
Materials and methods
Cells, plasmids, and viruses
The C8166 and SupT1 lymphocyte cell lines were used for
transfections of full-length SHIVs and as indicator cells to measure
infectivity and cytopathicity of the viruses used in this study. Both cell
lines were maintained in RPMI-1640, supplemented with 10 mM
Hepes buffer pH 7.3, 2 mM glutamine, 5 μg per ml gentamicin,
100 units/μg penicillin-streptomycin and 10% fetal bovine serum
(R10FBS). Rhesus macaque PBMCs were obtained from uninfected
animals and isolated on Ficoll/Hypaque gradients for p27 growthcurves. The 293 and TZM-bl cell lines were maintained in Dulbecco's
minimal essential medium (DMEM) with 10% fetal bovine serum and
the antibiotics described above. The derivation of SHIVKU-2MC4 has
been previously described (Joag et al., 1998). The pcDNA3.1(+)-
rhesus APOBEC3G-HA and pcDNA3.1(+)-rhesus APOBEC3F-V5 were
kindly provided by Dr. Nathaniel Landau (New York University School
of Medicine, New York, New York).
Construction of SHIVVif5A, SHIVVifHCCH(−) and SHIVVifSTOP
For the construction of SHIVVifHCCH(−), the PacI/SphI fragment
(nucleotides 5132 to 6452) from the p5'-SHIV4 was subcloned into
the pGEM-3Zf (+) vector (Promega). The histidine to alanine
substitution atposition110of Vifwas introducedusingoligonucleotides
(only sense strand shown) 5'-GCAGACATTTTACTGGCTAGCACT-
TATTTCC-3'. The cytidine to alanine substitution at position 116 of Vif
was introduced using oligonucleotides (only sense strand shown) 5'-
GCACTTATTTCCCTGCCTTTACAGCGGGAG-3'. The cysteines at positions
134 and 135 of Vif were substituted for alanines using the oligonucleo-
tides (only sense strand shown) 5'-CAACTGCTGTCTGCCGC-
CAGGTTCCCG-3'. The histidine to alanine substitution at position 144
of Vif was introduced using oligonucleotides (only sense strand shown)
5'-GGTTCCCGAGAGCTGCTAAGTACCAGGTACC-3'. All substitutionswere
made using the Quik-Change Mutagenesis Kit (Stratagene) following
the manufacturer's instructions. The resulting PacI/SphI fragment was
digested, isolated, and subcloned into full-length SHIVKU-2MC4. The
resulting plasmid was sequenced to ensure that the desired mutations
were introduced as expected.
For the construction of SHIVVif5A, the PacI/SphI fragment (nucleo-
tides 5132 to 6452) from full-length SHIVKU-2MC4 was subcloned into
the pGEM-3Zf (+) vector. The serine and leucine at positions 147 and
148 were substituted for alanines using the oligonucleotides (sense
strand shown) 5'-CCAGGTACCAGCCGCACAGTACTTAGCAC-3'. The
glutamine and tyrosine at positions 149 and 150 were substituted
for alanines using the oligonucleotides (sense strand shown) 5'-
CCAGGTACCAGCCGCAGCGGCCTTAGCACTGAAAGTAGTAAGC-3'. The
leucine at position 151 was substituted for an alanine using the
oligonucleotide (sense strand shown) 5'-GGTACCAGCCGCA-
GCGGCCGCAGCACTGAAGTAGTAAGCG-3'. All substitutions were
made using the Quik-Change Mutagenesis Kit (Stratagene) following
themanufacturer's instructions and virus constructed and prepared as
described above.
For the construction of SHIVVifSTOP, the tyrosine and leucine at
amino acid positions 28 and 29 were engineered to have stop codons
using site-directed mutagenesis in order to produce a full-length SHIV
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used to introduce these mutations was 5’-GCCTCATTAAAATAGTAG-
AAATATAAAACTAAAG-3' (only sense strand shown). The substitu-
tions were made using the Quik-Change Mutagenesis Kit (Stratagene)
following the manufacturer's instructions. The resulting PacI/SphI
fragment was digested, isolated, and subcloned into full-length
SHIVKU-2MC4. The resulting plasmid was sequenced to ensure that the
desired mutations were introduced as expected. For all three viruses,
the plasmids containing the full-length genomeswere transfected into
SupT1 cells as previously described (Stephens et al., 2002; Hout et al.,
2005). Stocks of SHIVVifHCCH(−), SHIVVif5A, and SHIVVifSTOP were
prepared, tittered on SupT1 cells, and stored at−86 °C.
Analysis of the replication of SHIVVif5A and SHIVVifHCCH(−) in
APOBEC3G/F positive and negative cells
C8166 (A3G/F positive) and SupT1 (A3G/F negative) cells were
inoculated with equivalent levels (25 ng) of parental SHIVKU-2MC4,
SHIVVif5A, SHIVVifHCCH(−), SHIVVifAAQYLA, or SHIVVifSTOP for 4 h at
37 °C. For rhesus PBMC, cells were isolated on Ficoll-Hypaque
gradients, stimulated for 48 h in R10FBS supplemented with
concanvalin A (10 μg/ml) and interleukin-2 (IL-2; 50 ng/ml). The
cells were washed, and inoculated with virus (25 ng) incubated in
R10FBS containing interleukin-2 (50 ng/ml) for 4 h. At 4 h, cells
were centrifuged, washed 3 times to remove the inoculum and
incubated in fresh medium (medium for the rhesus PBMC also
contained 50 ng/ml IL-2) at 37 °C for up to 15 days. Aliquots of
culture supernatants were obtained at 0, 1, 3, 5, 7, 9, 11, 13, and
15 days post-inoculation and the levels of p27 assessed using a
commercial p27 antigen capture kit (Zeptometrix).
APOBEC3G/F incorporation assays
Plasmids containing the genomes of the viruses (derived from
SHIVKU-2MC4) expressing each of the mutant Vif proteins described
above were co-transfected into 293 cells using PEI transfection
reagent (Ex-Gen 500, Fermentas) along with plasmids expressing
either HA-rhA3G or V5-rhA3F. At 48 h, virus containing super-
natants were harvested and clariﬁed by low speed centrifugation.
The clariﬁed supernatant was then subjected to ultracentrifugation
to pellet the virus (SW41 rotor, 247,000g, 1 h). The pellet was
resuspended in PBS (pH 7.4) and layered on a 20/60% sucrose step
gradient and again subject to ultracentrifugation (SW55Ti, 247,000g,
1 h). The virus (at the interface) was harvested, pelleted again by
ultracentrifugation described above, and resuspended in 200 μl of
1× PBS (pH 7.4). An aliquot was saved to determine the p27
content by antigen capture assay (Zeptometrix). The remaining
sample was boiled in sample reducing buffer. Equivalent amounts
of p27 were loaded on a 12% SDS-PAGE gel and transferred to
PVDF membranes. APOBEC3 proteins were detected by Western
blotting using an antibody directed against either the HA tag (HA-
probe; Santa Cruz) or V5 tag (Clone V5-10; Sigma). Blots were
stripped in 1× stripping buffer (62.5 mM Tris–HCl, pH 6.8 and 2%
SDS) and reprobed using a rabbit polyclonal antibody speciﬁc for
p27. As a control, plasmids expressing either rhA3G or rhA3F were
transfected into 293 cells using PEI transfection reagent (Ex-
Gen500, Fermentas). At 48 h post-transfection, cells were lysed in
1× RIPA and the nuclei were removed. Whole protein was
precipitated with methanol and resuspended in 2× sample
reducing buffer. Normalized to β-actin, the samples were run on
a 12%-SDS-PAGE gel, and probed with the antibodies stated above.
Stability of rhA3G and rhA3F in the presence of SHIV genomes
We determined if rhA3G or rhA3F were stable in the presence
of SHIVKU-2MC4, SHIVVifHCCH(−), SHIVVif5A, or SHIVVifSTOP. Full-lengthmutated SHIVs were co-transfected in a 2:1 ratio with either
APOBEC3G-HA or APOBEC3F-V5 using polyethylenimine transfec-
tion reagent (PEI, Fermentas). Twenty-four hours post-transfection,
the supernatant was removed and the cells were harvested and
lysed using 1× RIPA (50 mM Tris–HCl, pH 7.5; 50 mM NaCl; 0.5%
deoxycholate; 0.2% SDS; 10 mM EDTA). Following lysis, the nuclei
were removed by microcentrifugation at 14,000 rpm for 15 min.
The protein was precipitated using methanol, resuspended in 2×
sample reducing buffer, and boiled for 5 min. Proteins were
separated on a 10% SDS-PAGE gel and probed using commercially
available rabbit polyclonal HA antibody (HA-probe, Santa Cruz) for
rhA3G-HA or mouse monoclonal V5 antibody (Clone V5-10,
Sigma) for rhA3F. All samples were normalized to the amount of
beta-actin protein using a mouse monoclonal antibody (Novous
Biologicals) speciﬁc for beta-actin.
Hypermutation assays in the presence of rhA3G or rhA3F
Hypermutation of various SHIVs in the presence of rhesus
APOBEC3G/F 293 cells were transfected with SHIVKU-2MC4,
SHIVVifHCCH(−), SHIVVif5A, or SHIVVifSTOP in the presence of either
rhA3G or rhA3F using PEI transfection reagent (Ex-Gen, Fermen-
tas). Twenty-four hours post-transfection, cells were washed and
fresh DMEM was added. After 48 h, the supernatant containing
virus was subjected to low speed centrifugation. The resulting
supernatant was DNase-I-treated (Fermentas) at 37 °C for 30 min
to eliminate any trace of plasmid carry-over from the initial
transfection. The DNase-I-treated supernatant was titrated on TZM-
bl cells to both assess infectivity and hypermutation. Twenty-four
hours post-infection, total DNA cellular DNA was harvested and
extracted using the DNeasy kit and the manufacturer's instructions
(Qiagen). The DNA was used in a nested DNA polymerase chain
reaction to amplify a 300 base pair fragment of nef. The PCR
reaction was carried out using rTaq, the manufacturer's instruc-
tions (Takara), and the oligonucleotides listed below. 1 μl of the
ﬁrst PCR product was added to a nested reaction. The PCR
reactions were performed using an Applied Systems 2720 Thermal
Cycler with the following thermal proﬁle: 95 °C for 2 min, 1 cycle;
95 °C for 30 s, 48 °C for 30 s, 65 °C for 2 min, 35 cycles; 65 °C for
7 min. The PCR products were separated by electrophoresis,
isolated, puriﬁed, sequenced and sub-cloned into pGEM-TEasy
(Promega) as described below. Fifteen independent clones were
sequenced and assessed for each mutant SHIV as described above.
Restriction of Vif mutants on rhA3G or rhA3F
We determined the effect of the Vif mutants on the suppression of
rhA3G and rhA3F. Full-lengthmutated SHIVswere co-transfectedwith
either rhA3G or rhA3F using PEI transfection reagent (Ex-Gen500,
Fermentas). Forty-eight hours post-transfection, the supernatant was
harvested and puriﬁed by low speed centrifugation. Equivalent
amounts of p27 were serially diluted using 10-fold dilutions from
101 to 106 and used to inoculate TZM-bl cells . Forty-eight hours later,
the media was removed, cells washed with 1× PBS and the monolayer
ﬁxed using 0.8% formaldehyde-0.25% glutaraldehyde in phosphate-
buffered saline (1× PBS). The cells were washed and incubated in a
solution for 2 h at 37 °C in 4 mM potassium ferrocyanide, 4 mM
potassium ferricyanide, 4 mM magnesium chloride, and 0.4 mg X-gal
per ml. The reaction was stopped and the number of TCID50 were
calculated (Derdeyn et al., 2000; Wei et al., 2000).
Macaques analyzed in this study
Three rhesus macaques (Macaca mulatta: CX54, ER65, and I92)
were intravenously inoculated with 1 ml of undiluted culture
supernatant from SupT1 grown virus stocks (containing 104 TCID50
201K. Schmitt et al. / Virology 404 (2010) 187–203per ml). Three additional rhesus macaques (AS34, AS51, and AV18)
were inoculated with 104 TCID50 SHIVVifHCCH(−) (titered in SupT1
cells). The animals were housed in the AAALAC-approved animal
facility at the University of Kansas Medical Center. All aspects of the
animal studies were performed according to the institutional guide-
lines for animal care and use at the University of Kansas Medical
Center. Heparinized blood was collected weekly for the ﬁrst 4 weeks,
then at 2 week intervals for the next month and at monthly intervals
thereafter.
Assays for circulating CD4+ T cells
Changes in the levels of CD4+ T cells after viral inoculations were
monitored sequentially by ﬂow cytometric analysis (BD Biosciences).
T cell subsets were labeled with a commercially available anti-CD3/
CD4/CD8 mixture. T cell subsets from a normal uninfected macaque
were always performed at the same time to serve as a control for the
ﬂow cytometry analysis.
Processing of tissue samples at necropsy
At the time of euthanasia (26 or 28 weeks), all macaques in this
study were anesthetized by administration of 10 mg/kg ketamine
(IM) followed by intravenous administration of sodium phenobarbital
at 20–30 mg/kg. At the time of necropsy, all macaques were in a
healthy condition. A laparotomy was performed. The animal was
exsanguinated by aortic canulation and perfused with 1 l of cold
Ringer's saline. Lymphoid and non lymphoid tissues (heart, kidneys,
liver, lungs, mesenteric, inguinal and axillary lymph nodes, pancreas,
salivary gland, small intestine, spleen, thymus, and tonsils) were
obtained and aliquots of tissue snap frozen for DNA and RNA assays.
Aliquots of lymphoid tissueswere immersed in HBSS to quantify levels
of infectious virus in tissues using infectious centers assayswith SupT1
cells.
Sequence analysis of the vif, nef, and vpu genes
To determine the stability of the mutations that were introduced
into vif and assess whether these macaques acquired G-to-A
mutations, the vif, nef, and vpu genes were ampliﬁed from either
PBMCs at different time points during infection (vif) or from several
tissue DNA samples taken at necropsy (nef and vpu) that were positive
for viral RNA. One hundred nanograms of extracted genomic DNAwas
used in a nested DNA polymerase chain reaction (Takara, Madison,
WI) following the manufacturer's instructions. The oligonucleotides
employed during the ﬁrst round to amplify vifwere 5'-GGCTAAAATT-
ATCAAAGATTATGGAGG-3' (sense) and 5'-GGTGACATCCCTTGTTCA-
TCATGCC-3' (antisense), which corresponds to bases 5326–5352 and
5984–6008, respectively. The nested oligonucleotides were 5'-
GGAGGAGGAAAAGAGGTGGATAGCAGTTCCC-3' (sense) and 5'-CCAG-
TATTCCCAAGACCTTTGCC-3' (antisense), which corresponds to bases
5348–5378 and 5963–5985, respectively. The oligonucleotides used
during the ﬁrst round to amplify the nef gene were 5'-GGTGGAGC-
TATTTCCATGAGG-3' (sense) and 5'-GTCTTCTTGGACTGTAATAAA-
TCCC-3' (antisense), which corresponds to bases 9445–9465 and
9832–9856, respectively. The nested oligonucleotides were 5'-
CCATGAGGCGGTCCAGGCAGTCTAGAG-3' (sense) and 5'-CCTCCCAGT-
CCCCCCTTTTC-3' (antisense), which corresponds to bases 9458–9484
and 9814–9833, respectively. The oligonucleotides used during the
ﬁrst round to amplify the vpu gene were 5'-CCTAGACTAGAGCCCTG-
GAAGCATCC-3' (sense) and 5'-GTACCTCTGTATCATATGCTTTAGCAT-3'
(antisense), which corresponds to bases 6486–6511 and 7034–7061,
respectively. The nested oligonucleotides used were 5'-TTAGG-
CATCTCCTATGGCAGGAAGAAG-3' (sense) and 5'-CACAAAATA-
GAGTCCTGGTTGCTTCCT-3' (antisense), which corresponds to bases
6597–6623 and 7001–7027, respectively.For sequence analysis, the PCR products from three separate PCR
reactions were pooled and separated by electrophoresis in a 1.5%
agarose gel, isolated, and each PCR reaction directly sequenced.
Cycle sequencing reactions using the BigDye Terminator Cycle
Sequencing Ready Reaction Kit with AmpliTaq DNA polymerase, FS
(PE Applied Biosystems, Foster City, CA) sequence detection was
conducted with an Applied Biosystems 377 Prism XL automated
DNA sequencer and visualized using the ABI Editview program.
Sequences were compared to the sequence of SHIVKU-2MC4. A total of
615 nucleotides were analyzed from vif, 300 nucleotides analyzed
from nef, and 184 nucleotides from vpu using the SE Central
Software package. In order to isolate and analyze single sequences,
bulk PCR reactions were subcloned into the pGEM-T Easy (Promega)
cloning vector. Fifteen clones were selected, sequenced as described
above, and analyzed to assess the number of G-to-A substitutions
that occurred.
Plasma virus loads
Plasma viral RNA loads were determined on RNA extracted from
1 ml of EDTA-treated plasma. Virus was pelleted using ultracentrifu-
gation (Beckman SW55Ti, 250,000g, 2 h) and RNA extracted using the
Qiagen viral RNA kit (Qiagen). RNA samples were analyzed by real-
time RT-PCR using gag primers and a 5'FAM and 3'TAMRA labeled
Taqman probe that is homologous to the SIV gag gene as previously
described (Hofmann-Lehmann et al., 2000). Standard curves were
prepared using a series of six ten-fold dilutions of viral SIV gag RNA of
known concentration. The sensitivity of the assay was 100 RNA
equivalents per ml. Samples were analyzed in triplicate and the
number of RNA equivalents per ml of plasma were calculated. Viral
RNA was also quantiﬁed from in visceral tissues using this primer/
probe reaction. In order to quantify the amount of viral RNA, GAPDH
was used as a control and data is presented as copies per 106 GAPDH
molecules (Marcario et al., 2008).
Immunoprecipitation assays
To determine if the macaques developed antibodies to SHIV
proteins following inoculation, the plasma at 12 weeks and at
necropsy was used in immunoprecipitation assays. C8166 cells
were inoculated with approximately 104 TCID50 of SHIVKU-2MC4 for
5 days. The cells were then incubated in methionine/cysteine-free
media for 2 h and radiolabeled with 500 μCi of 35Smethionine/
cysteine for 15 h. The cells were lysed in 1 ml of 1× RIPA buffer and
nuclei were removed by centrifugation. The cell lysates were
incubated overnight at 4 °C with 10 μl of plasma from each macaque
and protein A Sepharose beads. The immunoprecipitates bound to
the beads were washed three times in 1× RIPA, resuspended in 75 μl
of 2× sample reducing buffer, and boiled for 5 min. Proteins were
separated on a 10% SDS-PAGE gel and visualized by autoradiography.
Controls included pooled prebleed plasma from macaques (negative
control) and plasma from macaques that had been previously
inoculated with a non-pathogenic SHIV (SHIVTM, positive control).
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